Abstract
Introduction
Fuelled by the pandemic flu threat, the influenza market has expanded rapidly
in recent years. This growing commercial opportunity has encouraged companies
to develop new technologies and increase manufacturing capacity for influenza
vaccines and antivirals. The H1N1 pandemic will stimulate further growth, but
also confronts industry and public health stakeholders with new challenges.
Scope of this research
- Strategic analysis of the current influenza market across the US, Japan,
France, Germany, Italy, Spain and the UK and of key companies in the sector
- Thorough assessment of commercial and clinical factors influencing and
shaping the influenza treatment and prevention market
- Patient-based forecast model for the seasonal flu vaccine market with
three different scenarios modelling the long-term impact of the current
pandemic
- In-depth analysis of both influenza vaccine and antiviral pipeline
candidates and discussion of their future potential
Research and analysis highlights
The influenza sector has benefited from the increased disease awareness and
funding due to the pandemic flu scare. Maintaining this momentum in the coming
years will be a key challenge. New technologies in manufacturing, adjuvants
and delivery will drive increased product differentiation in the currently
highly commoditized flu vaccines market.
Datamonitor believes that the most likely scenario for the long-term impact of
the current H1N1 pandemic is a transient boost for seasonal flu vaccination,
expanding the 7 major markets' size from $2.8 billion in 2008/2009 to over $4
billion in 2010/2011, followed by a period of stagnation caused by
immunization fatigue.
While Tamiflu will remain the leading influenza antiviral for the foreseeable
future, resistance is becoming an increasing issue for Roche' s drug.
Biocryst' s Phase III drug peramivir could claim an attractive niche market in
hospitalized patients, while Biota' s inhaled pipeline candidate CS-8958 has an
interesting long-acting profile.
Key reasons to purchase this research
- Review the clinical and commercial factors driving new product decisions
in influenza vaccines and the strategies of key players in the market
- Size the market with patient-based scenario forecasts of the seasonal
vaccines market and a thorough analysis of the vaccine and antiviral pipeline
- Understand concerns, unmet needs and future opportunities in influenza
prevention and therapy
| 
View Cart
